Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NovaDx and Tera Biotechnology see disease marker breakthrough:

This article was originally published in Clinica

Executive Summary

US companies NovaDx and Tera Biotechnology have signed a letter of intent jointly to develop a technology to shorten the time taken by researchers to identify disease markers in blood. The companies believe they can reduce the time from a current five-to-ten years to just months. The technology would have direct application in diagnostics product development, for which the two enterprises will form a separate company. The research will be conducted in NovaDx' San Diego laboratories while Tera, based in the same city, will provide gene cloning technology. The agreement should be signed by August 1st, 1995.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT092025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel